Apogee Therapeutics (APGE) Operating Leases (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Operating Leases data on file, last reported at $4.9 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 37.18% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 37.18% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 37.83% from the prior year.
• Operating Leases for Q1 2026 stood at $4.9 million, down from $5.3 million in the prior quarter.
• Over the last five years, Operating Leases for APGE reached as high as $9.3 million in Q3 2024 and fell as low as $600000.0 in Q1 2024.
• Historically, Operating Leases has averaged $5.2 million across 4 years, with a median of $5.6 million in 2025.
• On a YoY basis, Operating Leases climbed as much as 1200.0% in 2025 and fell as far as 37.83% in 2025.
• Year by year, Operating Leases stood at $933000.0 in 2023, then jumped by 821.44% to $8.6 million in 2024, then plunged by 37.83% to $5.3 million in 2025, then decreased by 8.33% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $4.9 million in Q1 2026, $5.3 million in Q4 2025, and $5.8 million in Q3 2025.